These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35296886)

  • 1. Contemporary and emerging pharmacotherapeutic agents for the treatment of Lassa viral haemorrhagic fever disease.
    Joseph AA; Fasipe OJ; Joseph OA; Olatunji OA
    J Antimicrob Chemother; 2022 May; 77(6):1525-1531. PubMed ID: 35296886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
    Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
    mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combating Lassa Fever in West African Sub-Region: Progress, Challenges, and Future Perspectives.
    Aloke C; Obasi NA; Aja PM; Emelike CU; Egwu CO; Jeje O; Edeogu CO; Onisuru OO; Orji OU; Achilonu I
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lassa fever in post-conflict sierra leone.
    Shaffer JG; Grant DS; Schieffelin JS; Boisen ML; Goba A; Hartnett JN; Levy DC; Yenni RE; Moses LM; Fullah M; Momoh M; Fonnie M; Fonnie R; Kanneh L; Koroma VJ; Kargbo K; Ottomassathien D; Muncy IJ; Jones AB; Illick MM; Kulakosky PC; Haislip AM; Bishop CM; Elliot DH; Brown BL; Zhu H; Hastie KM; Andersen KG; Gire SK; Tabrizi S; Tariyal R; Stremlau M; Matschiner A; Sampey DB; Spence JS; Cross RW; Geisbert JB; Folarin OA; Happi CT; Pitts KR; Geske FJ; Geisbert TW; Saphire EO; Robinson JE; Wilson RB; Sabeti PC; Henderson LA; Khan SH; Bausch DG; Branco LM; Garry RF;
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2748. PubMed ID: 24651047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lassa fever - the road ahead.
    Garry RF
    Nat Rev Microbiol; 2023 Feb; 21(2):87-96. PubMed ID: 36097163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
    Hulseberg CE; Fénéant L; Szymańska-de Wijs KM; Kessler NP; Nelson EA; Shoemaker CJ; Schmaljohn CS; Polyak SJ; White JM
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
    Safronetz D; Rosenke K; Westover JB; Martellaro C; Okumura A; Furuta Y; Geisbert J; Saturday G; Komeno T; Geisbert TW; Feldmann H; Gowen BB
    Sci Rep; 2015 Oct; 5():14775. PubMed ID: 26456301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lassa virus diversity and feasibility for universal prophylactic vaccine.
    Lukashevich IS; Paessler S; de la Torre JC
    F1000Res; 2019; 8():. PubMed ID: 30774934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of antiviral therapeutics in animal models of Lassa fever.
    Warner BM; Siragam V; Stein DR
    Curr Opin Virol; 2019 Aug; 37():84-90. PubMed ID: 31357140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic basis underlying Lassa fever endemics in the Mano River region, West Africa.
    Li Y
    Virology; 2023 Feb; 579():128-136. PubMed ID: 36669329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current research for a vaccine against Lassa hemorrhagic fever virus.
    Warner BM; Safronetz D; Stein DR
    Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifty years of imported Lassa fever: a systematic review of primary and secondary cases.
    Wolf T; Ellwanger R; Goetsch U; Wetzstein N; Gottschalk R
    J Travel Med; 2020 Jul; 27(4):. PubMed ID: 32219400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lassa fever in West African sub-region: an overview.
    Ogbu O; Ajuluchukwu E; Uneke CJ
    J Vector Borne Dis; 2007 Mar; 44(1):1-11. PubMed ID: 17378212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population structure of Lassa Mammarenavirus in West Africa.
    Forni D; Sironi M
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32294960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine platforms for the prevention of Lassa fever.
    Purushotham J; Lambe T; Gilbert SC
    Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The search for animal models for Lassa fever vaccine development.
    Lukashevich IS
    Expert Rev Vaccines; 2013 Jan; 12(1):71-86. PubMed ID: 23256740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection.
    Branco LM; Grove JN; Boisen ML; Shaffer JG; Goba A; Fullah M; Momoh M; Grant DS; Garry RF
    Virol J; 2011 Oct; 8():478. PubMed ID: 22023795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the cryptic nature of Lassa fever in West Africa.
    Gibb R; Moses LM; Redding DW; Jones KE
    Pathog Glob Health; 2017 Sep; 111(6):276-288. PubMed ID: 28875769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of Lassa virus infection in suspected and confirmed cases in Ondo State, Nigeria.
    Salu OB; Amoo OS; Shaibu JO; Abejegah C; Ayodeji O; Musa AZ; Idigbe I; Ezechi OC; Audu RA; Salako BL; Omilabu SA
    Pan Afr Med J; 2020; 36():253. PubMed ID: 33014249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
    mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.